Core Viewpoint - Lifeward Ltd. has successfully closed a public offering of 4,000,000 ordinary shares and accompanying warrants, raising approximately $2.6 million in gross proceeds, which will be used for commercial efforts and working capital [1][3]. Group 1: Offering Details - The public offering price was set at $0.65 per ordinary share and associated ordinary warrant, with the warrants having an exercise price of $0.65 and expiring five years from the issuance date [1]. - H.C. Wainwright & Co. served as the exclusive placement agent for the offering [2]. - The potential additional gross proceeds from the exercise of the ordinary warrants, if fully exercised, could amount to another $2.6 million [3]. Group 2: Company Overview - Lifeward Ltd. is a leader in innovative medical technology aimed at transforming the lives of individuals with physical limitations or disabilities [1]. - The company offers a range of products including the ReWalk Exoskeleton, AlterG Anti-Gravity System, ReStore Exo-Suit, and MyoCycle FES System, focusing on rehabilitation and recovery [6]. - Founded in 2001, Lifeward operates in the United States, Israel, and Germany, with a mission to drive innovation in the field of physical rehabilitation [6].

Core Viewpoint - Lifeward Ltd. has announced a public offering of 4,000,000 ordinary shares and accompanying warrants at a price of $0.65 per share, aiming to raise approximately $2.6 million for commercial efforts and working capital [1][3]. Group 1: Offering Details - The public offering includes 4,000,000 ordinary shares and warrants to purchase an additional 4,000,000 shares at the same price of $0.65 [1]. - The ordinary warrants will be exercisable immediately and will expire five years from the issuance date [1]. - The expected gross proceeds from the offering are approximately $2.6 million before deducting fees and expenses [3]. Group 2: Use of Proceeds - The net proceeds from the offering will be used for continuing commercial efforts, working capital, and general corporate purposes [3]. Group 3: Regulatory Information - The offering is being conducted under a registration statement on Form S-1, which was declared effective by the SEC on June 25, 2025 [4]. - A preliminary prospectus has been filed with the SEC and is available on their website [4]. Group 4: Company Overview - Lifeward Ltd. specializes in innovative medical technology aimed at transforming the lives of individuals with physical limitations or disabilities [6]. - The company’s product portfolio includes the ReWalk Exoskeleton, AlterG Anti-Gravity System, ReStore Exo-Suit, and MyoCycle FES System [6]. - Founded in 2001, Lifeward operates in the United States, Israel, and Germany [6].

Core Viewpoint - The recent ruling by an Administrative Law Judge establishes that the ReWalk Exoskeleton is a "reasonable and necessary" medical device for enabling paralyzed individuals to walk, paving the way for Medicare coverage and potentially broader commercial insurance access [1][2]. Group 1: Legal and Regulatory Developments - The ALJ ruling supports an appeal by a Medicare beneficiary for coverage of the ReWalk Exoskeleton, affirming its medical necessity for individuals with spinal cord injuries [1]. - This ruling builds on a prior decision by the Centers for Medicare & Medicaid Services (CMS) in April 2024, which finalized a reimbursement pathway for personal exoskeletons [2]. Group 2: Company Innovations and Products - The ReWalk Exoskeleton is noted as the only personal exoskeleton that allows paralyzed individuals to navigate stairs and curbs, in addition to walking in everyday environments [2]. - The latest model, ReWalk 7, received FDA clearance in March 2025 and is now commercially available in the United States [2]. Group 3: Company Mission and Vision - Lifeward aims to transform the lives of individuals with physical limitations through innovative medical technology, focusing on expanding data and programs for the paralyzed community [2][3]. - The company is committed to delivering groundbreaking solutions that empower individuals to regain mobility and improve their quality of life [3].

Lifeward (LFWD) Conference Summary Company Overview - **Company**: Lifeward Limited - **Industry**: Medical Devices, specifically focused on rehabilitation technologies such as exoskeletons and functional electrical stimulation devices Key Points and Arguments Future Growth and Positioning - Lifeward has developed leading innovative technologies aimed at fundamentally changing lives, with a focus on commercialization [4][6] - The company has achieved significant milestones, including Medicare coverage for personal exoskeletons, which positions them for future growth [9][31] Product Portfolio - Lifeward's product lineup includes: - **ReWalk**: A personal exoskeleton for restoring functional walking [12][43] - **AlterG**: An antigravity system for rehabilitation [35][38] - **MyoCycle FES**: A functional electrical stimulation bike for therapy [40][41] - **ReStore Exosuit**: A soft exoskeleton primarily for stroke patients [43][44] Market Access and Reimbursement - The company has made strides in reimbursement coverage, with significant contracts established in the U.S. and Germany [29][31] - Lifeward is focusing on expanding into the commercial market and enhancing relationships with workers' compensation [30][32] Market Size and Potential - The total addressable market for ReWalk in the U.S. is approximately 15,000 eligible candidates, with an additional 2,000 in Germany, indicating a substantial growth opportunity [34] - The company is targeting a broader market with its various products, aiming for profitability through market penetration [34][71] Financial Performance and Path to Profitability - Lifeward expects to achieve revenue between $28 million to $30 million for the current year, with a goal of reaching breakeven at $40 million to $45 million in revenue by 2026 [47][71] - The company has improved gross margins through efficient operations and product mix [48][65] Product Development and Innovation - Lifeward has launched new versions of its products, enhancing user experience with features like smoother movement and better control [18][19][21] - Continuous feedback from users has driven product improvements, emphasizing the importance of user experience in rehabilitation technologies [27][28] Industry Dynamics - The medical device industry is fragmented, presenting opportunities for future consolidation as Lifeward continues to grow and integrate its product lines [46][47] - The company is strategically positioned to leverage its clinic presence to drive referrals and enhance product adoption [67][68] Additional Important Information - Lifeward's products are manufactured in various locations, with ReWalk produced in Israel and other products made in the U.S. [72] - The company has navigated tariff concerns effectively, with protocols in place to mitigate potential impacts [72] This summary encapsulates the key insights from the Lifeward conference, highlighting the company's strategic direction, product offerings, market potential, and financial outlook.

Core Insights - Lifeward is transitioning from technology validation to commercial growth with the appointment of Mark Grant as CEO, effective June 2, 2025, marking a critical phase for the company [1][2] - The rehabilitation technology industry is experiencing a strategic return, with Lifeward's ReWalk system gaining Medicare coverage and commercial insurance support, indicating a growing demand and willingness to pay [5][9] Company Developments - Mark Grant has over 30 years of experience in the medical technology field, focusing on commercialization and channel development, previously holding executive roles at Medtronic and IMRA Surgical [3][4] - Under Grant's leadership, Lifeward aims to significantly reduce non-GAAP operating losses in 2025 through revenue growth and cost optimization, with projected revenue growth from $25.7 million in 2024 to a range of $28 million to $30 million in 2025 [11][12] Product Portfolio - Lifeward's core products include ReWalk, AlterG, MyoCycle, and ReStore, addressing neurological rehabilitation, orthopedic recovery, and home training, covering the entire rehabilitation pathway from hospital to community [10][13] - The ReWalk system has received FDA approval and Medicare coverage, with a new generation, ReWalk 7, set to launch in 2025, showcasing significant sales growth and international market expansion [16][18] Market Positioning - The rehabilitation technology market is witnessing a second value discovery phase, with Lifeward positioned to capitalize on this trend due to its established product structure and initial market mechanisms [12] - Lifeward's products are designed for various medical conditions, including spinal cord injuries, brain injuries, strokes, and orthopedic/sports medicine, enhancing customer lifetime value and repeat purchase potential [10][9]

Core Viewpoint - Lifeward Ltd. has appointed Mark Grant as the new President and CEO, effective June 2, 2025, to lead the company in its next growth phase, while outgoing CEO Larry Jasinski will assist in the transition [1][2][3] Company Leadership - Mark Grant brings 30 years of experience in commercial leadership and strategic solutions, having managed teams across multiple geographies and critical functions [2][5] - The Board of Directors expressed confidence in Grant's ability to drive innovations that improve the lives of individuals with physical limitations [3][4] Recent Achievements - Lifeward has made significant progress in the past year, including achieving Medicare payment for the ReWalk exoskeleton and building a strong pipeline of ReWalk cases [3][4] Product Portfolio - The ReWalk exoskeleton is highlighted as a key product in Lifeward's portfolio, which includes other innovative solutions aimed at enhancing the quality of life for individuals with disabilities [4][10] Inducement Grant - In connection with Grant's appointment, Lifeward's Board approved an inducement award of 400,000 options to purchase ordinary shares, subject to specific terms and conditions [8][9] Company Background - Lifeward, founded in 2001, operates in the United States, Israel, and Germany, focusing on developing life-changing solutions for physical rehabilitation and recovery [10][11]

Company Overview - Lifeward, Ltd. is a global leader in innovative medical technology aimed at transforming the lives of individuals with physical limitations or disabilities [3][4] - The company designs, develops, and commercializes solutions that provide functional and health benefits across various care settings, including clinical environments and home care [3] - Lifeward's product portfolio includes notable innovations such as the ReWalk Exoskeleton, AlterG Anti-Gravity system, MyoCycle FES System, and ReStore Exo-Suit [3] Upcoming Events - Larry Jasinski, CEO of Lifeward, will present at the Sidoti May Virtual Investor Conference on May 21, 2025, at 10:00 AM EDT [1][2] - The company will also conduct virtual one-on-one meetings with investors on May 21-22, 2025, with free registration available for interested parties [2]

Company Performance - Lifeward reported a quarterly loss of $0.46 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.33, but an improvement from a loss of $0.73 per share a year ago [1] - The company's revenues for the quarter ended March 2025 were $5.03 million, missing the Zacks Consensus Estimate by 16.24% and down from $5.28 million year-over-year [3] - Over the last four quarters, Lifeward has surpassed consensus EPS estimates only once and has missed revenue estimates three times [2][3] Market Performance - Lifeward shares have declined approximately 16.8% since the beginning of the year, contrasting with the S&P 500's gain of 0.2% [4] - The current Zacks Rank for Lifeward is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [7] Future Outlook - The consensus EPS estimate for the upcoming quarter is -$0.25 on revenues of $6.47 million, and for the current fiscal year, it is -$0.77 on revenues of $29.02 million [8] - The estimate revisions trend for Lifeward is mixed, and future earnings expectations will depend on management's commentary during the earnings call [4][5] Industry Context - Lifeward operates within the Zacks Internet - Software industry, which is currently ranked in the top 31% of over 250 Zacks industries [9] - The performance of Lifeward's stock may be influenced by the overall outlook for the industry, as top-ranked industries tend to outperform lower-ranked ones significantly [9]

Lifeward (LFWD) Q1 2025 Earnings Call May 15, 2025 08:30 AM ET Company Participants Mike Lawless - CFOLarry Jasinski - CEOBen Haynor - Managing Director Conference Call Participants Yale Jen - Senior Managing Director & Senior Biotech AnalystSwayampakula Ramakanth - Managing Director & Senior Equity Analyst Operator Good day, and welcome to the Q1 twenty twenty five LifeForward, Inc. Earnings Conference Call. All participants will be in listen only mode. Please note this event is being recorded. I would now ...

Financial Data and Key Metrics Changes - Q1 2025 revenues were $5 million, down $300,000 year on year, but the LIFO business was up year on year [5][12] - On a non-GAAP basis, adjusted operating loss was $4.6 million compared to $5.5 million for the same periods [19] - GAAP gross margin was 42.2% compared to 26.4% in Q1 2024, while non-GAAP adjusted gross margin was 42.2% compared to 33.7% [17][18] Business Line Data and Key Metrics Changes - Revenue from ReWalk robotics products was $1.6 million, while Alter G products generated $3.4 million, with Alter G sales growing by 19% year on year [14] - The number of ReWalk rentals increased to 36, primarily in Germany, indicating strong future sales potential [6][15] - Alter G has shown significant growth of 1970% in the last two quarters [7] Market Data and Key Metrics Changes - The U.S. pipeline has over 120 qualified leads, up over 70% from two quarters ago [6][15] - The company has expanded partnerships with Alter G distributors, including four new business partners [6] Company Strategy and Development Direction - The company is focused on profitable revenue growth, tight expense control, and cash management [5] - A partnership with CoreLife aims to enhance progress in the workers' compensation segment [6] - The company anticipates a sales range of $28 million to $30 million for 2025, with expectations of a reduced operating loss by Q4 [20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in future growth based on a strong pipeline and recent FDA approvals [6][20] - The leadership transition is expected to be smooth, with a solid foundation in place for future growth [11] Other Important Information - The company ended Q1 with $5.7 million in cash and equivalents and no debt, raising an additional $500,000 post-quarter [19] - The company is working collaboratively with Medicare Administrative Contractors to improve claims processing predictability [10] Q&A Session Questions and Answers Question: What is the assessment of recent tariff situations? - The company is monitoring the situation closely and has planned for alternatives within the market, with minimal impact expected on the ReWalk production in Israel [25][26] Question: How does the company support its full-year revenue guidance despite lower Q1 revenue? - Confidence is based on strong momentum in the Ultra G product line and a robust pipeline of leads, indicating growth potential [28] Question: Can you elaborate on the ReWalk seven's differences from the previous version? - The ReWalk seven features significant improvements in usability, power, and control, while maintaining a similar price point [36][39] Question: How does the expanded Mylan partnership benefit the commercial sales force? - The partnership allows access to a new segment for home use, leveraging historical data to drive sales [42] Question: What is the market size for workers' compensation in the U.S.? - The workers' compensation market represents about 6% to 7% of the overall market, providing a significant opportunity for growth [47] Question: How has the Alter G acquisition performed? - The integration has stabilized, and recent product launches have shown strong growth, particularly in international markets [54][56]